Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of ION904 in Healthy Participants
NCT04731623Phase 1Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Feb 2021
- Primary completion
- Aug 2021
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypertension (HTN) and heart failure (HF) comparing ION904 with Placebo (2 arms). Primary endpoints: Number of Participants With at Least One Treatment-emergent Adverse Event, Severity and dose relationship of TEAE and 2 more. Started Feb 2021; status: completed.
02
Drugs
tonlamarsen
03
Conditions
hypertension (HTN)heart failure (HF)
Beyond the preview
Go deeper on NCT04731623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04731623.